231 related articles for article (PubMed ID: 18162243)
1. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries).
Vesikari T; Itzler R; Matson DO; Santosham M; Christie CD; Coia M; Cook JR; Koch G; Heaton P
Int J Infect Dis; 2007 Nov; 11 Suppl 2():S29-35. PubMed ID: 18162243
[TBL] [Abstract][Full Text] [Related]
2. Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq.
Ciarlet M; Schödel F
Vaccine; 2009 Dec; 27 Suppl 6():G72-81. PubMed ID: 20006144
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants.
Goveia MG; Rodriguez ZM; Dallas MJ; Itzler RF; Boslego JW; Heaton PM; DiNubile MJ;
Pediatr Infect Dis J; 2007 Dec; 26(12):1099-104. PubMed ID: 18043445
[TBL] [Abstract][Full Text] [Related]
4. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe.
Vesikari T; Itzler R; Karvonen A; Korhonen T; Van Damme P; Behre U; Bona G; Gothefors L; Heaton PM; Dallas M; Goveia MG
Vaccine; 2009 Dec; 28(2):345-51. PubMed ID: 19879226
[TBL] [Abstract][Full Text] [Related]
5. The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine.
Dennehy PH; Goveia MG; Dallas MJ; Heaton PM
Int J Infect Dis; 2007 Nov; 11 Suppl 2():S36-42. PubMed ID: 18162245
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States.
Wang FT; Mast TC; Glass RJ; Loughlin J; Seeger JD
Pediatrics; 2010 Feb; 125(2):e208-13. PubMed ID: 20100757
[TBL] [Abstract][Full Text] [Related]
7. Rotavirus live, oral, pentavalent vaccine.
Tom-Revzon C
Clin Ther; 2007 Dec; 29(12):2724-37. PubMed ID: 18201590
[TBL] [Abstract][Full Text] [Related]
8. The new pentavalent rotavirus vaccine composed of bovine (strain WC3) -human rotavirus reassortants.
Clark HF; Offit PA; Plotkin SA; Heaton PM
Pediatr Infect Dis J; 2006 Jul; 25(7):577-83. PubMed ID: 16804425
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life.
Block SL; Vesikari T; Goveia MG; Rivers SB; Adeyi BA; Dallas MJ; Bauder J; Boslego JW; Heaton PM;
Pediatrics; 2007 Jan; 119(1):11-8. PubMed ID: 17200266
[TBL] [Abstract][Full Text] [Related]
10. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.
Vesikari T; Clark HF; Offit PA; Dallas MJ; DiStefano DJ; Goveia MG; Ward RL; Schödel F; Karvonen A; Drummond JE; DiNubile MJ; Heaton PM
Vaccine; 2006 May; 24(22):4821-9. PubMed ID: 16621194
[TBL] [Abstract][Full Text] [Related]
11. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine.
Ciarlet M; Sani-Grosso R; Yuan G; Liu GF; Heaton PM; Gottesdiener KM; Arredondo JL; Schödel F
Pediatr Infect Dis J; 2008 Oct; 27(10):874-80. PubMed ID: 18756184
[TBL] [Abstract][Full Text] [Related]
12. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants.
Clark HF; Bernstein DI; Dennehy PH; Offit P; Pichichero M; Treanor J; Ward RL; Krah DL; Shaw A; Dallas MJ; Laura D; Eiden JJ; Ivanoff N; Kaplan KM; Heaton P
J Pediatr; 2004 Feb; 144(2):184-90. PubMed ID: 14760258
[TBL] [Abstract][Full Text] [Related]
13. Vaccines: the pentavalent rotavirus vaccine: discovery to licensure and beyond.
Heaton PM; Ciarlet M
Clin Infect Dis; 2007 Dec; 45(12):1618-24. PubMed ID: 18198497
[TBL] [Abstract][Full Text] [Related]
14. RotaTeq: a three-dose oral pentavalent reassortant rotavirus vaccine.
Chandran A; Santosham M
Expert Rev Vaccines; 2008 Dec; 7(10):1475-80. PubMed ID: 19053204
[TBL] [Abstract][Full Text] [Related]
15. Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children.
Vesikari T; Karvonen AV; Majuri J; Zeng SQ; Pang XL; Kohberger R; Forrest BD; Hoshino Y; Chanock RM; Kapikian AZ
J Infect Dis; 2006 Aug; 194(3):370-6. PubMed ID: 16826486
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children.
Grant LR; Watt JP; Weatherholtz RC; Moulton LH; Reid R; Santosham M; O'Brien KL
Pediatr Infect Dis J; 2012 Feb; 31(2):184-8. PubMed ID: 22252206
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses.
Goveia MG; Suprun L; Itzler RF; McFetridge R; Dallas MJ; Kuter BJ
Pediatr Infect Dis J; 2010 Mar; 29(3):263-5. PubMed ID: 19949360
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on pentavalent rotavirus vaccine (RotaTeq) in the prevention of rotavirus gastroenteritis in Europe.
Plosker GL
BioDrugs; 2010 Dec; 24(6):411-4. PubMed ID: 21043548
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency.
Goveia MG; DiNubile MJ; Dallas MJ; Heaton PM; Kuter BJ;
Pediatr Infect Dis J; 2008 Jul; 27(7):656-8. PubMed ID: 18520448
[TBL] [Abstract][Full Text] [Related]
20. Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization.
Christie CD; Duncan ND; Thame KA; Onorato MT; Smith HD; Malcolm LG; Itzler RF; Dinubile MJ; Heaton PM
Pediatrics; 2010 Dec; 126(6):e1499-506. PubMed ID: 21115586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
